| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10915823 | Nuclear Medicine and Biology | 2016 | 8 Pages |
Abstract
We have developed the novel PET tracer, [11C]UCB-A, that can be used to measure SV2A expression in vivo. The dosimetry allows up to 5 administrations of 400Â MBq of [11C]UCB-A in humans. Apart from measuring drug occupancy, as we have shown, the tracer can potentially be used to compare SV2A expression between individuals because of the rather narrow range of baseline VT values. This will have to be further validated in human studies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
![[11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2Â A](/preview/png/10915823.png "First Page Preview: [11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2Â A")
Authors
Sergio Estrada, Mark Lubberink, Alf Thibblin, Margareta Sprycha, Tim Buchanan, Nathalie Mestdagh, Benoit Kenda, Joel Mercier, Laurent Provins, Michel Gillard, Dominique Tytgat, Gunnar Antoni,